Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week high on Thursday . The stock traded as high as C$0.32 and last traded at C$0.31, with a volume of 982216 shares changing hands. The stock had previously closed at C$0.28.
Hemostemix Stock Performance
The company has a market capitalization of C$32.67 million, a price-to-earnings ratio of -18.75 and a beta of 0.20. The firm has a 50-day simple moving average of C$0.13 and a two-hundred day simple moving average of C$0.09.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- How Can Investors Benefit From After-Hours Trading
- Bloom Energy: Powering the Future With Decentralized Energy
- Compound Interest and Why It Matters When Investing
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Consumer Staples Stocks, Explained
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
